The Role of Maintenance Chemotherapy, Immunotherapy, Induction Dose Reduction in Elderly Patients and Double Induction in the Treatment of Adult Acute Myeloid Leukemia. Four Randomized Studies of the AML Cooperative Group1

1989 ◽  
pp. 1-10 ◽  
Author(s):  
Th. Büchner ◽  
W. Hiddemann ◽  
P. Koch ◽  
H. Pielken ◽  
D. Urbanitz ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Elderly Patients ◽  
Dose Reduction ◽  
Myeloid Leukemia ◽  
Maintenance Chemotherapy ◽  
Induction Dose ◽  
Randomized Studies ◽  
Acute Myeloid

scholarly journals The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study

2016 ◽  
Vol 33 (4) ◽  
pp. 273-280 ◽  
Author(s):  
Anıl Tombak ◽  
Mehmet Ali Uçar ◽  
Aydan Akdeniz ◽  
Eyüp Naci Tiftik ◽  
Deniz Gören Şahin ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Elderly Patients ◽  
Multicenter Study ◽  
Myeloid Leukemia ◽  
Retrospective Multicenter Study ◽  
Acute Myeloid

Dose-related periorbital edema following sorafenib in a patient with acute myeloid leukemia

2018 ◽  
Vol 25 (8) ◽  
pp. 2035-2037 ◽  
Author(s):  
Craig W Freyer ◽  
James K Mangan
Keyword(s):  
Acute Myeloid Leukemia ◽  
Adverse Event ◽  
Dose Reduction ◽  
Myeloid Leukemia ◽  
Potential Role ◽  
Growth Factor Receptor ◽  
Platelet Derived Growth Factor ◽  
Periorbital Edema ◽  
Acute Myeloid

We describe a case of dose-related periorbital edema in a patient with FLT3-mutated acute myeloid leukemia taking sorafenib and voriconazole that resolved following sorafenib dose reduction. We hypothesize that the mechanism of this adverse event may be related to the inhibition of platelet-derived growth factor receptor (PDGFR) by sorafenib. Clinicians should be aware of this possible dose-related adverse event and the potential role of sorafenib dose reduction when on concurrent voriconazole.

Role of FLT3 gene mutations in acute myeloid leukemia: effect on course of disease and results of therapy

2019 ◽  
Vol XIV (1) ◽  
Author(s):  
A.M. Radzhabova ◽  
S.V. Voloshin ◽  
I.S. Martynkevich ◽  
A.A. Kuzyaeva ◽  
V.A. Shuvaev ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Gene Mutations ◽  
Course Of Disease ◽  
Acute Myeloid

scholarly journals Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development

2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Yiyi Yao ◽  
Fenglin Li ◽  
Jiansong Huang ◽  
Jie Jin ◽  
Huafeng Wang
Keyword(s):  
Bone Marrow ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Chemotherapy Resistance ◽  
Bone Marrow Microenvironment ◽  
Cytotoxic Effects ◽  
High Relapse Rate ◽  
Underlying Mechanisms ◽  
Acute Myeloid

AbstractDespite the advances in intensive chemotherapy regimens and targeted therapies, overall survival (OS) of acute myeloid leukemia (AML) remains unfavorable due to inevitable chemotherapy resistance and high relapse rate, which mainly caused by the persistence existence of leukemia stem cells (LSCs). Bone marrow microenvironment (BMM), the home of hematopoiesis, has been considered to play a crucial role in both hematopoiesis and leukemogenesis. When interrupted by the AML cells, a malignant BMM formed and thus provided a refuge for LSCs and protecting them from the cytotoxic effects of chemotherapy. In this review, we summarized the alterations in the bidirectional interplay between hematopoietic cells and BMM in the normal/AML hematopoietic environment, and pointed out the key role of these alterations in pathogenesis and chemotherapy resistance of AML. Finally, we focused on the current potential BMM-targeted strategies together with future prospects and challenges. Accordingly, while further research is necessary to elucidate the underlying mechanisms behind LSC–BMM interaction, targeting the interaction is perceived as a potential therapeutic strategy to eradicate LSCs and ultimately improve the outcome of AML.

Sign in / Sign up

Export Citation Format

Share Document